This study presents results of a prospective multicenter clinical trial of 99 women treated with MR guided focused ultrasound (MRgFUS) for symptomatic uterine leiomyomas to assess treatment durability and to evaluate potential demographic, imaging, and technical characteristics associated with lasting clinical outcomes. Following treatment, there was an improvement in symptoms, with a significant decrease in mean symptom severity score at the 6, 12, 24 and 36 month follow up (p<0.001). In a multivariate model, a new parameter of interest, the ratio of non-perfused volume to total fibroid volume (NPV/TFV) was found to be predictive of durable clinical success (p=0.03).
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords